Horizon Discovery offers new CRISPR reagents

By The Science Advisory Board staff writers

March 30, 2021 -- Horizon Discovery, a PerkinElmer company, is expanding its gene editing and modulation portfolio to include a new family of CRISPR modulation reagents for CRISPR interference (CRISPRi).

CRISPRi allows scientists to understand biological pathways, processes, and disease pathologies by repressing genes at the transcription level. The new reagents include synthetic single-guide RNAs for CRISPRi, as well as deactivated Cas9 (dCas9)-SALL1-SDS3 transcriptional repressors for messenger RNA (mRNA) and lentiviral formats.

The new technologies will repress genes in most cell lines, over any length of time, and at any scale -- from single-gene readouts to high-throughput studies, according to the firm. The proprietary dCas9-SALL1-SDS3 repressor was developed in-house at Horizon Discovery.

"CRISPRi is gene knockdown, not knockout. It's CRISPR without the cut, so it offers a temporary and nuanced approach which is ideal for researchers looking to mimic cellular effects of small molecule drugs or do multiplexed gene interrogation," said Alan Fletcher, senior vice president of life sciences at PerkinElmer.

Copyright © 2021 scienceboard.net

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.